Conflicted Evidence No More—French National Study Reveals mRNA COVID-19 Vaccines Cause Irregular Menstrual Bleeding

Scientists from EPI-PHARE a shared unit of the French National Agency for the Safety of Medicines and Health Products (ANSM) and the French National Health Insurance (Cnam) conducted a study led by J&eacute;r&eacute;mie&nbsp;Botton, PhD, PharmD, MPH and colleagues designed a national study randomly matching non-pregnant 15-50 years old women who had a hospital discharge diagnosis of heavy menstrual bleeding between May 12, 2021, and August 31, 2022 (cases) matching with up to 30 controls of the same age, place of residence, social deprivation index, and contraceptive use profile at the date of case hospital admission (index date). The case-control study tapped into the comprehensive data of the French National Health Data System as part of an investigation into COVID-19 vaccinated women.&nbsp; The COVID-19 vaccine has been inconsistently associated with an increased risk of heavy menstrual bleeding in previous studies. Hence, the goal of the investigators in this study, aiming to assess the risk of heavy menstrual bleeding requiring hospital care following COVID-19 vaccination according to the number of doses received and the time elapsed since vaccination. The study result: the mRNA COVID-19 vaccines are associated with an increased risk of heavy menstrual bleeding during the three-month period following primary series vaccination. No increased risk was found beyond 3&nbsp;months after primary vaccination nor following booster doses.
The recent bombshell given the conflicting evidence TrialSite has reported on was published in the October edition of the peer-reviewed journal Vaccine.